Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting

Interventional Cardiology Clinics

Volumn 6, Issue 1, 2017, Pages 151-166

  Gross, Lisa ^a   Sibbing, Dirk ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

CABG; Guidance of treatment; PCI; Platelet function testing; Platelet reactivity; Risk prediction; Tailored antiplatelet therapy; Transfusion algorithm

Indexed keywords

PURINERGIC P2Y12 RECEPTOR; ANTITHROMBOCYTIC AGENT;

ANTICOAGULATION; CORONARY ARTERY BYPASS GRAFT; HEART MUSCLE REVASCULARIZATION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; ACUTE CORONARY SYNDROME; BLOOD; BLOOD CLOTTING PARAMETERS; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; THROMBOCYTE; THROMBOSIS;

ACUTE CORONARY SYNDROME; BLOOD PLATELETS; CORONARY ARTERY BYPASS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POSTOPERATIVE COMPLICATIONS; THROMBOSIS;

EID: 84997282823     PISSN: 22117458     EISSN: 22117466     Source Type: Journal    
DOI: 10.1016/j.iccl.2016.08.011     Document Type: Review

References (67)

1. 1 Authors/Task Force members, Windecker, S., Kolh, P., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:37 (2014), 2541–2619.
2. 2 Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:14 (2007), 1505–1516.
3. 3 Sibbing, D., Steinhubl, S.R., Schulz, S., et al. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 56:4 (2010), 317–318.
4. 4 Serebruany, V.L., Steinhubl, S.R., Berger, P.B., et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:2 (2005), 246–251.
5. 5 Mega, J.L., Simon, T., Collet, J.P., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:16 (2010), 1821–1830.
6. 6 Frelinger, A.L. 3rd, Bhatt, D.L., Lee, R.D., et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 61:8 (2013), 872–879.
7. 7 Sibbing, D., Braun, S., Morath, T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53:10 (2009), 849–856.
8. 8 Tantry, U.S., Bonello, L., Aradi, D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62:24 (2013), 2261–2273.
9. 9 Aradi, D., Kirtane, A., Bonello, L., et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36:27 (2015), 1762–1771.
10. 10 Lordkipanidze, M., Platelet function tests. Semin Thromb Hemost 42:3 (2016), 258–267.
11. 11 Bonello, L., Paganelli, F., Arpin-Bornet, M., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 5:8 (2007), 1630–1636.
12. 12 Breet, N.J., van Werkum, J.W., Bouman, H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303:8 (2010), 754–762.
13. 13 Campo, G., Fileti, L., de Cesare, N., et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 56:18 (2010), 1447–1455.
14. 14 Campo, G., Parrinello, G., Ferraresi, P., et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57:25 (2011), 2474–2483.
15. 15 Cuisset, T., Frere, C., Quilici, J., et al. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Am J Cardiol 104:8 (2009), 1078–1082.
16. 16 Cuisset, T., Grosdidier, C., Loundou, A.D., et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv 6:8 (2013), 854–863.
17. 17 Gurbel, P.A., Bliden, K.P., Navickas, I.A., et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 160:2 (2010), 346–354.
18. 18 Mangiacapra, F., Patti, G., Barbato, E., et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv 5:3 (2012), 281–289.
19. 19 Marcucci, R., Gori, A.M., Paniccia, R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119:2 (2009), 237–242.
20. 20 Parodi, G., Marcucci, R., Valenti, R., et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306:11 (2011), 1215–1223.
21. 21 Price, M.J., Endemann, S., Gollapudi, R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:8 (2008), 992–1000.
22. 22 Price, M.J., Angiolillo, D.J., Teirstein, P.S., et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124:10 (2011), 1132–1137.
23. 23 Sibbing, D., Bernlochner, I., Schulz, S., et al. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. J Am Coll Cardiol 60:5 (2012), 369–377.
24. 24 Stone, G.W., Witzenbichler, B., Weisz, G., et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:9892 (2013), 614–623.
25. 25 Geisler, T., Langer, H., Wydymus, M., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27:20 (2006), 2420–2425.
26. 26 Hochholzer, W., Trenk, D., Bestehorn, H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48:9 (2006), 1742–1750.
27. 27 Bonello, L., Tantry, U.S., Marcucci, R., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:12 (2010), 919–933.
28. 28 Alexopoulos, D., Galati, A., Xanthopoulou, I., et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60:3 (2012), 193–199.
29. 29 Bonello, L., Mancini, J., Pansieri, M., et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 10:10 (2012), 1999–2005.
30. 30 Parodi, G., Valenti, R., Bellandi, B., et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61:15 (2013), 1601–1606.
31. 31 Price, M.J., Berger, P.B., Teirstein, P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:11 (2011), 1097–1105.
32. 32 Collet, J.P., Cuisset, T., Range, G., et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:22 (2012), 2100–2109.
33. 33 Michelson, A.D., Frelinger, A.L. 3rd, Braunwald, E., et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 30:14 (2009), 1753–1763.
34. 34 Mokhtar, O.A., Lemesle, G., Armero, S., et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb Res 126:2 (2010), e147–e149.
35. 35 Parodi, G., Bellandi, B., Venditti, F., et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 109:2 (2012), 214–218.
36. 36 Patti, G., Pasceri, V., Vizzi, V., et al. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol 107:7 (2011), 995–1000.
37. 37 Sibbing, D., Schulz, S., Braun, S., et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 8:2 (2010), 250–256.
38. 38 Tsukahara, K., Kimura, K., Morita, S., et al. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circ J 74:4 (2010), 679–685.
39. 39 Kirtane, A.J., Parikh, P.B., Stuckey, T.D., et al. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: “Window” Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). JACC Cardiovasc Interv 8:15 (2015), 1978–1987.
40. 40 Bonello, L., Camoin-Jau, L., Armero, S., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 103:1 (2009), 5–10.
41. 41 Aradi, D., Tornyos, A., Pinter, T., et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 63:11 (2014), 1061–1070.
42. 42 Mayer, K., Schulz, S., Bernlochner, I., et al. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thromb Haemost 112:2 (2014), 342–351.
43. 43 Siller-Matula, J.M., Francesconi, M., Dechant, C., et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 167:5 (2013), 2018–2023.
44. 44 Trenk, D., Stone, G.W., Gawaz, M., et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 59:24 (2012), 2159–2164.
45. 45 Karkouti, K., Wijeysundera, D.N., Yau, T.M., et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 44:10 (2004), 1453–1462.
46. 46 Ranucci, M., Baryshnikova, E., Castelvecchio, S., et al., Surgical and Clinical Outcome Research (SCORE) Group. Major bleeding, transfusions, and anemia: the deadly triad of cardiac surgery. Ann Thorac Surg 96:2 (2013), 478–485.
47. 47 Kwak, Y.L., Kim, J.C., Choi, Y.S., et al. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 56:24 (2010), 1994–2002.
48. 48 Mahla, E., Suarez, T.A., Bliden, K.P., et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 5:2 (2012), 261–269.
49. 49 Schimmer, C., Hamouda, K., Sommer, S.P., et al. The predictive value of multiple electrode platelet aggregometry (multiplate) in adult cardiac surgery. Thorac Cardiovasc Surg 61:8 (2013), 733–743.
50. 50 Ranucci, M., Colella, D., Baryshnikova, E., et al. Surgical, Clinical Outcome Research G. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J Anaesth 113:6 (2014), 970–976.
51. 51 Mannacio, V., Meier, P., Antignano, A., et al. Individualized strategy for clopidogrel suspension in patients undergoing off-pump coronary surgery for acute coronary syndrome: a case-control study. J Thorac Cardiovasc Surg 148:4 (2014), 1299–1306.
52. 52 Reed, G.W., Kumar, A., Guo, J., et al. Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45–a pilot study. Clin Cardiol 38:2 (2015), 92–98.
53. 53 Ferraris, V.A., Saha, S.P., Oestreich, J.H., et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg 94:5 (2012), 1761–1781.
54. 54 Shore-Lesserson, L., Manspeizer, H.E., DePerio, M., et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 88:2 (1999), 312–319.
55. 55 Royston, D., von Kier, S., Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth 86:4 (2001), 575–578.
56. 56 Nuttall, G.A., Oliver, W.C., Santrach, P.J., et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 94:5 (2001), 773–781 [discussion: 5A–6A].
57. 57 Avidan, M.S., Alcock, E.L., Da Fonseca, J., et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 92:2 (2004), 178–186.
58. 58 Ak, K., Isbir, C.S., Tetik, S., et al. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. J Card Surg 24:4 (2009), 404–410.
59. 59 Westbrook, A.J., Olsen, J., Bailey, M., et al. Protocol based on thromboelastograph (TEG) out-performs physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery: a pilot study. Heart Lung Circ 18:4 (2009), 277–288.
60. 60 Girdauskas, E., Kempfert, J., Kuntze, T., et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg 140:5 (2010), 1117–1124.e2.
61. 61 Weber, C.F., Gorlinger, K., Meininger, D., et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 117:3 (2012), 531–547.
62. 62 Agarwal, S., Johnson, R.I., Shaw, M., Preoperative point-of-care platelet function testing in cardiac surgery. J Cardiothorac Vasc Anesth 29:2 (2015), 333–341.
63. 63 Corredor, C., Wasowicz, M., Karkouti, K., et al. The role of point-of-care platelet function testing in predicting postoperative bleeding following cardiac surgery: a systematic review and meta-analysis. Anaesthesia 70:6 (2015), 715–731.
64. 64 Cuisset, T., Cayla, G., Frere, C., et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?. EuroIntervention 5:3 (2009), 325–329.
65. 65 Wang, X.D., Zhang, D.F., Zhuang, S.W., et al. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol 34:5 (2011), 332–338.
66. 66 Ari, H., Ozkan, H., Karacinar, A., et al. The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial). Int J Cardiol 157:3 (2012), 374–380.
67. 67 Hazarbasanov, D., Velchev, V., Finkov, B., et al. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis 34:1 (2012), 85–90.